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1850automatically measured to distinguish TCFA from
ThCFA with 99% accuracy. After development using
ex vivo VH-OCT data, the AI algorithm was applied
in vivo for 13 patients during heart catheterization.
The analysis was exempted from institutional review
board approval by the Office of the Institutional
Review Board at the University of Texas Health
Science Center in San Antonio. The sensitivities and
specificities for fibrous, calcium, and lipid compared
with those provided by the 2 expert readers were 86%
and 84%, 80% and 81%, and 82% and 80%, respec-
tively. Example ex vivo and in vivo images are
shown, demonstrating the ability to identify accu-
rately fibrous, lipid, and calcium (Figure 1).
The traditional classification scheme for IVOCT
visualized arterial tissue includes fibrous, lipid, and
calcium (4). This study is the first report to auto-
matically classify tissue components with AI based on
histological validation and extension into in vivo
patient images obtained during heart catheterization.
The results suggest that AI based on histological
validation can allow identification of clinical
morphologies.
Limitations of the present study were misregis-
tration and shallow OCT light penetration depth that
limited the potential accuracy of any morphological
classifier. To quantify these errors, the pathologists
assigned each of the co-registered histology images 1
of 4 morphological categories: fibrocalcific; patho-
logical intimal thickening; ThCFA; and TCFA. The
ground truth segmented dataset was likewise
classified and then compared with histological
classifications. Resulting accuracy of all 4 morphol-
ogies was 91%, which suggested an error of 9% from
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Cardiac Involvement in Fabry Disease
Using Cardiovascular Magnetic
Resonance ImagingFabry disease (FD) is an X-linked lysosomal storage
disorder resulting in accumulation of sphingolipids in
the heart, which leads to progressive left ventricular
hypertrophy (LVH), fibrosis, and premature death (1).
Although previous studies have tracked changes in
mass using echocardiography (2), cardiovascular
magnetic resonance (CMR) is the gold standard for
reproducible measurement of mass and offers insight
into the relationship between sphingolipid deposi-
tion, LVH, and fibrosis in FD over time, using T1 and
T2 mapping, as well as late gadolinium enhancement
(LGE). (3) The aim of this study was to define LV
changes in FD over time and to consider use of
enzyme replacement therapy (ERT).
This was a multicenter longitudinal study using
CMR in 100 patients with FD (gene positive; 44%
men; mean age 44  14 years). Local clinical gover-
nance and ethical approval was obtained (NRES
London 14/LO/1948, UHB clinical governance:
RRK6621). Participants underwent 1.5-T CMR
(Avanto, Siemens Healthcare, Erlangen, Germany)
using a standard protocol that quantified LV mass and
tissue characterization with T1 [Modified Look-Locker
Inversion recovery sequence, 3(3)3(3)5 sampling
scheme] and T2 mapping pre-contrast and inversion
recovery imaging for LGE post-contrast. T1 maps were
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(A) Change in left ventricular (LV) mass. Gradient per year: men: no enzyme replacement therapy (ERT) þ1.9% versus ERT þ2.5%; women: no ERT þ1.1% versus
ERT þ0.9%; p < 0.05. No significant differences comparing no ERT versus ERT. (B) Change in T1 time. Gradient per year: men: no ERT 7.6 ms vs. ERT 2.4 ms;
women: no ERT 8.3 ms vs. ERT þ6.2 ms; p < 0.05. A significant difference was present comparing no ERT versus ERT in women only (p < 0.001).
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1851analyzed using semi-automated segmentation at the
mid-LV cavity, with a 20:20 percentage offset and an
average of all segments taken (following artefactual
segment exclusion), which gave global T1 mapping.
LGE was quantified using a threshold of 6 SDs above
the mean signal intensity of the reference
myocardium.
The median duration of follow-up was 37 months
(interquartile range [IQR]: 20 to 60 months), with a
median of 2 follow-up visits per patient (range 2 to 6).
Fifty percent of patients were on ERT at baseline (37
on agalsidase-alpha and 13 on agalsidase-beta). At
baseline, men had higher indexed LV mass (LVMi)
and maximum wall thickness (MWT) compared with
women (median LVMi: 111.8 g/m2 [IQR: 85.4 to 149.2
g/m2] vs. 62.7 g/m2 [IQR: 56.7 to 82.5 g/m2]; MWT:
16 mm [IQR: 12 to 18 mm] vs. 10 mm [IQR: 9 to 12 mm];
p < 0.001 for both). Thirty-one patients (33%) had
LGE at baseline (men: 49% vs. women: 21%;
p ¼ 0.008), with a similar mass of LGE seen (men 8.5 g
[IQR: 3.2 to 19.6 g] vs. women: 7.4 g [IQR: 1.4 to 15.2
g]; p ¼ 0.359).
There was an increase in absolute LVM over time
(n ¼ 100), with a gradient of 2.4% (95% confidence
interval [CI]: 1.8% to 3.1%) per year in men (p < 0.001)
and 1.0% (95% CI: 0.3 to 1.7%) per year in women
(p ¼ 0.005). Native T1 decreased over time in men
(3.4 ms per year; 95% CI: 6.4 to 0.4; p ¼ 0.029),
but no significant change was observed in women
(p ¼ 0.831). Mass of LGE increased by 36.6% (95% CI:14.0% to 63.7%) per year in men (p < 0.001) and by
12.0% (95% CI: 2.0% to 23.0%) per year in women
(p ¼ 0.011). There were no changes in the proportions
of male and female patients with chronic kidney
disease, ischemic heart disease, or hypertension over
the study period.
Five patients received ERT during follow-up and
were excluded from subgroup analysis by ERT status
(Figure 1). ERT usage differed by sex, with 32 of 41
(78%) men on ERT compared with 18 of 54 (33%)
women (p < 0.001). The increase in LVM over time
remained significant despite the use of ERT in both
men (ERT: 2.5% per year; 95% CI: 1.9% to 3.0%;
p < 0.001; no ERT: 1.9% per year; 95% CI: 0.3% to
3.6%; p ¼ 0.020) and women (ERT: 0.9% per year;
95% CI: 0.1% to 1.8%; p ¼ 0.025; no ERT: 1.1% per
year; 95% CI: 0.3% to 1.9%; p ¼ 0.005). T1 decreased
over time in men not on ERT (7.6 ms per year; 95%
CI: 12.6 to 2.5; p ¼ 0.003), although there was a
tendency to a smaller reduction on ERT (2.4 ms;
95% CI: 4.6 to 0.1; p ¼ 0.039; between groups:
p ¼ 0.064). However, in women, T1 decreased over
time in those not on ERT (8.3 ms per year; 95% CI:
12.6 to 3.9; p < 0.001) but increased in the ERT
group (þ6.2 ms per year; 95% CI: 2.0 to 10.4;
p ¼ 0.004; between groups: p < 0.001).
This longitudinal CMR study was consistent with a
sex-specific myocardial response in FD. Men had
more advanced cardiac involvement at baseline and
progressed at a greater rate than women, despite use
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1852of disease-modifying therapy. During this study,
these changes were less clear in women, and the
impact of ERT was more pronounced. Although LV
mass increased in women on ERT, T1 time increased,
which could be consistent with either a sex-
dependent response to therapy or a difference in
myocardial response to storage. Limitations included
the small sample size and lack of established prog-
nostic T1 data, which made the relevance and
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Indices and Response to Cardiac
Resynchronization TherapyCardiac resynchronization therapy (CRT) is a well-
established heart failure (HF) treatment and exerts
its effects through restoration of synchronous ven-
tricular contraction. Myocardial work (MW) is a novel
semiautomatic echocardiographic method which
characterizes the efficacy of the left ventricular (LV)
contraction by evaluating the amount of energy loss
(wasted work [WW]) and the amount of work per-
formed (constructive work [CW]) for each myocardial
segment (1). We investigated regional differences in
CW and WW between the septum and the lateral wall,
its potential implications for CRT response, as well as
the pattern of changes occurring early after CRT im-
plantation. The review board of the Leiden University
Medical Center approved this retrospective analysis
of clinically acquired data and waived the need for
patient written informed consent.
A total of 168 patients (71% men, mean age 65  10
years) with HF and sinus rhythm were included.
Speckle-tracking echocardiography was used to
assess MW at baseline and early after CRT implanta-
tion (within the first 5 days). LV global longitudinal
strain, noninvasive blood pressure measurements,
and valves opening and closure times were integrated
to construct pressure-strain loops. CW and WW of the
septal and lateral walls were calculated as the average
values of basal and mid-ventricular segments. CRT
response was defined as a decrease in LV end-systolic
volume $15 % at 6-month follow-up. The interob-
server and intraobserver variability of MW indices
was assessed calculating the intraclass correlation
coefficient (ICC) on 35 randomly selected patients.
Both interobserver and intraobserver variability was
excellent for segmental CW (ICC >0.93) and accept-
able for segmental WW (ICC >0.75).
Table 1 summarizes baseline characteristics and
regional MW indices before and after CRT implanta-
tion in the overall population, CRT responders, and
nonresponders. Nonischemic etiology of HF was
significantly more frequent in CRT responders
(p ¼ 0.027). At baseline, CRT responders demon-
strated significantly larger septal WW (p ¼ 0.038) and
lateral CW (p ¼ 0.005) compared with nonresponders.
